시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 망막정맥폐쇄증 치료 시장 보고서(2025년)
Retinal Vein Occlusion Treatment Global Market Report 2025
상품코드 : 1825893
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,471,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,354,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,236,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

망막정맥폐쇄증 치료 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년 연평균 성장률(CAGR)은 6.9%로 31억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 비용 효율성 및 상환 정책, 비침습적 치료에 대한 환자 선호도, 전 세계 의료비 지출 증가, 고령화 인구 증가, 신약 및 치료법 개발 등에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 유전자 치료의 발전, 약물전달을 위한 나노기술, 진단의 인공지능(AI), 원격의료 및 원격 모니터링, 환자 중심 기술 개발 등이 있습니다.

향후 5년간 6.9%의 성장률 전망은 지난번 전망치보다 0.2% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰로 인해 프랑스와 벨기에에서 개발된 마이크로카테터와 혈전용해제의 가격이 급등하여 시력 회복 기간이 길어지고 망막 전문 의료비 상승을 초래하여 미국 내 첨단 유리체내 치료의 도입을 방해할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

망막정맥폐쇄증 치료 시장의 성장은 안질환의 유병률 증가로 인해 증가할 것으로 예상됩니다. 안질환에는 가벼운 염증이나 감염부터 녹내장, 백내장, 황반변성, 당뇨망막병증과 같은 심각한 문제까지 시력에 영향을 미치는 다양한 장애가 포함됩니다. 안질환 증가 요인으로는 고령화, 당뇨병과 고혈압의 증가 등을 꼽을 수 있습니다. 망막정맥폐쇄증 치료는 시력저하를 예방하고 관련 합병증에 대처하기 위해 혈류를 회복하고 염증을 억제하는 데 초점을 맞추고 있습니다. 예를 들어, 미국 질병예방통제센터는 2024년 1월에 40세 이상의 미국인 중 340만 명 이상이 실명 또는 시각장애를 앓고 있으며, 이 숫자는 2030년까지 두 배로 증가할 것으로 예상했습니다. 이러한 안질환의 증가가 망막정맥폐쇄증 치료 시장의 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Retinal vein occlusion (RVO) treatment encompasses various approaches aimed at managing complications from blocked retinal blood vessels, focusing on reducing edema and preventing further vision loss.

The primary conditions treated for retinal vein occlusion are central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). CRVO involves a blockage of the central retinal vein, which can lead to vision impairment due to disrupted blood flow and potential retinal damage. Diagnosis often includes optical coherence tomography, fundoscopic examination, and fluorescein angiography. Treatments may involve anti-vascular endothelial growth factor (Anti-VEGF) agents, corticosteroids, and other options. These treatments are used by hospitals, clinics, research institutions, academic facilities, and similar entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The retinal vein occlusion treatment market research report is one of a series of new reports from The Business Research Company that provides retinal vein occlusion treatment market statistics, including retinal vein occlusion treatment industry global market size, regional shares, competitors with a retinal vein occlusion treatment market share, detailed retinal vein occlusion treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinal vein occlusion treatment industry. This retinal vein occlusion treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The retinal vein occlusion treatment market size has grown strongly in recent years. It will grow from $2.26 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to the adoption of combination therapies targeting multiple aspects of disease pathophysiology, the growing prevalence of diabetes and hypertension expanded access to healthcare services and specialized retinal care, clinical trials demonstrating the efficacy of new treatment modalities, and the development of anti-VEGF therapies.

The retinal vein occlusion treatment market size is expected to see strong growth in the next few years. It will grow to $3.16 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to cost-effectiveness and reimbursement policies, patient preferences for non-invasive treatments, increased healthcare spending globally, an increasing aging population, and the development of new drugs and therapies. Major trends in the forecast period include gene therapy advancements, nanotechnology for drug delivery, artificial intelligence (AI) in diagnostics, telemedicine and remote monitoring, and the development of patient-centric technologies.

The forecast of 6.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced intravitreal therapies by inflating prices of microcatheters and thrombolytic agents developed in France and Belgium, resulting in prolonged vision recovery and higher retinal specialty costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the retinal vein occlusion treatment market is anticipated to increase due to the rising prevalence of eye conditions. Eye conditions encompass a range of disorders affecting vision, from minor irritations and infections to serious issues such as glaucoma, cataracts, macular degeneration, and diabetic retinopathy. Factors contributing to the rise in eye conditions include an aging population and the growing rates of diabetes and hypertension. Retinal vein occlusion treatment focuses on restoring blood flow and reducing inflammation to prevent vision loss and manage related complications. For example, the Centers for Disease Control and Prevention reported in January 2024 that over 3.4 million Americans aged 40 and older were blind or visually impaired, with this number expected to double by 2030. This increase in eye conditions is driving growth in the retinal vein occlusion treatment market.

Key players in the retinal vein occlusion treatment market are developing innovative products such as interchangeable biosimilars to expand treatment options and improve patient access. An interchangeable biosimilar is a biologic drug closely similar to an existing reference biologic, used as an alternative for managing inflammation and fluid leakage. For instance, in May 2024, Biocon Biologics Limited, based in India, received approval from the US Food and Drug Administration for Yesafili (aflibercept-jbvf), an interchangeable biosimilar of EYLEA (aflibercept). This drug serves as a vascular endothelial growth factor (VEGF) inhibitor and is used to treat various ophthalmic conditions, including neovascular age-related macular degeneration (wet AMD), macular edema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (myopic CNV).

In April 2022, Samsung Biologics Co. Ltd., a South Korea-based biotechnology company, acquired Samsung Bioepis for $2.3 billion. This acquisition is expected to boost Samsung Bioepis' sales, operating margins, and capabilities in biosimilar and novel drug development. Samsung Bioepis Co. Ltd. is a South Korean biopharmaceutical company that offers treatment for retinal vein occlusion with its biosimilar product BYOOVIZ (ranibizumab-nuna).

Major companies operating in the retinal vein occlusion treatment market are Roche Holding AG, Bayer AG, Novartis International AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Chengdu Kanghong Pharmaceutical Group Co. Ltd., Spark Therapeutics Inc., Genentech Inc., Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Aerpio Pharmaceuticals Inc., REGENXBIO Inc., Stealth BioTherapeutics Corp., Adverum Biotechnologies Inc., Graybug Vision Inc., Oxurion NV, PanOptica Inc., Clearside Biomedical Inc.

North America was the largest region in the retinal vein occlusion treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the retinal vein occlusion treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The retinal vein occlusion treatment market consists of revenues earned by entities by providing services such as laser therapy, medication administration, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinal vein occlusion treatment market also includes sales of vitrectomy equipment, and optical coherence tomography (OCT) devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Retinal Vein Occlusion Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on retinal vein occlusion treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for retinal vein occlusion treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The retinal vein occlusion treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Retinal Vein Occlusion Treatment Market Characteristics

3. Retinal Vein Occlusion Treatment Market Trends And Strategies

4. Retinal Vein Occlusion Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Retinal Vein Occlusion Treatment Growth Analysis And Strategic Analysis Framework

6. Retinal Vein Occlusion Treatment Market Segmentation

7. Retinal Vein Occlusion Treatment Market Regional And Country Analysis

8. Asia-Pacific Retinal Vein Occlusion Treatment Market

9. China Retinal Vein Occlusion Treatment Market

10. India Retinal Vein Occlusion Treatment Market

11. Japan Retinal Vein Occlusion Treatment Market

12. Australia Retinal Vein Occlusion Treatment Market

13. Indonesia Retinal Vein Occlusion Treatment Market

14. South Korea Retinal Vein Occlusion Treatment Market

15. Western Europe Retinal Vein Occlusion Treatment Market

16. UK Retinal Vein Occlusion Treatment Market

17. Germany Retinal Vein Occlusion Treatment Market

18. France Retinal Vein Occlusion Treatment Market

19. Italy Retinal Vein Occlusion Treatment Market

20. Spain Retinal Vein Occlusion Treatment Market

21. Eastern Europe Retinal Vein Occlusion Treatment Market

22. Russia Retinal Vein Occlusion Treatment Market

23. North America Retinal Vein Occlusion Treatment Market

24. USA Retinal Vein Occlusion Treatment Market

25. Canada Retinal Vein Occlusion Treatment Market

26. South America Retinal Vein Occlusion Treatment Market

27. Brazil Retinal Vein Occlusion Treatment Market

28. Middle East Retinal Vein Occlusion Treatment Market

29. Africa Retinal Vein Occlusion Treatment Market

30. Retinal Vein Occlusion Treatment Market Competitive Landscape And Company Profiles

31. Retinal Vein Occlusion Treatment Market Other Major And Innovative Companies

32. Global Retinal Vein Occlusion Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Retinal Vein Occlusion Treatment Market

34. Recent Developments In The Retinal Vein Occlusion Treatment Market

35. Retinal Vein Occlusion Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기